Chinese Drug Regulators Extend Rare Fast-track Approval For J&J Drug
This article was originally published in PharmAsia News
HONG KONG - In an extremely rare case of fast-track approval for a special class of medicines, Chinese drug regulators have given the green light for a Johnson & Johnson drug to be launched nationwide before the completion of clinical trials inside China
You may also be interested in...
HONG KONG - San Francisco-based FibroGen announced that Chinese regulators approved the start of clinical trials of novel therapy FG-4592 for anemia associated with chronic kidney disease. The approval was expedited through China's two-year-old special approval procedure, or "green channel.
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).